Molecular Targets of Honokiol: A Promising Phytochemical for Effective Cancer Management

Enzymes

Volumn 36, Issue , 2014, Pages 175-193

  Averett, Courey ^a   Arora, Sumit ^a   Zubair, Haseeb ^a   Singh, Seema ^a   Bhardwaj, Arun ^a   Singh, Ajay P ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Anticancer effects; Honokiol; Molecular targets; Natural products

Indexed keywords

MAGNOLIA;

EID: 84919433898     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-802215-3.00009-4     Document Type: Chapter

References (78)

1. Newman D.J., Cragg G.M., Snader K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 2003, 66:1022-1037.
2. Vainio H., Weiderpass E. Fruit and vegetables in cancer prevention. Nutr. Cancer 2006, 54:111-142.
3. Esumi T., Makado G., Zhai H., Shimizu Y., Mitsumoto Y., Fukuyama Y. Efficient synthesis and structure-activity relationship of honokiol, a neurotrophic biphenyl-type neolignan. Bioorg. Med. Chem. Lett. 2004, 14:2621-2625.
4. Wolf I., O'Kelly J., Wakimoto N., Nguyen A., Amblard F., Karlan B.Y., Arbiser J.L., Koeffler H.P. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int. J. Oncol. 2007, 30:1529-1537.
5. Arora S., Bhardwaj A., Srivastava S.K., Singh S., McClellan S., Wang B., Singh A.P. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One 2011, 6:e21573.
6. Luo Y., Xu Y., Chen L., Luo H., Peng C., Fu J., Chen H., Peng A., Ye H., Xie D., Fu A., Shi J., Yang S., Wei Y. Preparative purification of anti-tumor derivatives of honokiol by high-speed counter-current chromatography. J. Chromatogr. A 2008, 1178:160-165.
7. Zhao C., Liu Z.Q. Comparison of antioxidant abilities of magnolol and honokiol to scavenge radicals and to protect DNA. Biochimie 2011, 93:1755-1760.
8. Tsai S.K., Huang C.H., Huang S.S., Hung L.M., Hong C.Y. Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: Influence of L-NAME and aspirin. Pharmacology 1999, 59:227-233.
9. Kuribara H., Stavinoha W.B., Maruyama Y. Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side-effects in mice. J. Pharm. Pharmacol. 1999, 51:97-103.
10. Hu H., Zhang X.X., Wang Y.Y., Chen S.Z. Honokiol inhibits arterial thrombosis through endothelial cell protection and stimulation of prostacyclin. Acta Pharmacol. Sin. 2005, 26:1063-1068.
11. Liou K.T., Lin S.M., Huang S.S., Chih C.L., Tsai S.K. Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Med. 2003, 69:130-134.
12. Bai X., Cerimele F., Ushio-Fukai M., Waqas M., Campbell P.M., Govindarajan B., Der C.J., Battle T., Frank D.A., Ye K., Murad E., Dubiel W., Soff G., Arbiser J.L. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J. Biol. Chem. 2003, 278:35501-35507.
13. Li Z., Liu Y., Zhao X., Pan X., Yin R., Huang C., Chen L., Wei Y. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 140:95-102.
14. Ma L., Chen J., Wang X., Liang X., Luo Y., Zhu W., Wang T., Peng M., Li S., Jie S., Peng A., Wei Y., Chen L. Structural modification of honokiol, a biphenyl occurring in Magnolia officinalis: The evaluation of honokiol analogues as inhibitors of angiogenesis and for their cytotoxicity and structure-activity relationship. J. Med. Chem. 2011, 54:6469-6481.
15. Hibasami H., Achiwa Y., Katsuzaki H., Imai K., Yoshioka K., Nakanishi K., Ishii Y., Hasegawa M., Komiya T. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int. J. Mol. Med. 1998, 2:671-673.
16. Arora S., Singh S., Piazza G.A., Contreras C.M., Panyam J., Singh A.P. Honokiol: A novel natural agent for cancer prevention and therapy. Curr. Mol. Med. 2012, 12:1244-1252.
17. Kong Z.L., Tzeng S.C., Liu Y.C. Cytotoxic neolignans: An SAR study. Bioorg. Med. Chem. Lett. 2005, 15:163-166.
18. Praveen K.V., Gajendra R.R., Vo D.D., Chakravarty S., Chandrasekhar S., Gree R. Synthesis and neurite growth evaluation of new analogues of honokiol, a neolignan with potent neurotrophic activity. Bioorg. Med. Chem. Lett. 2012, 22:1439-1444.
19. Kim Y.S., Lee J.Y., Park J., Hwang W., Lee J., Park D. Synthesis and microbiological evaluation of honokiol derivatives as new antimicrobial agents. Arch. Pharm. Res. 2010, 33:61-65.
20. Luo Y., Xu Y., Chen L., Hu J., Peng C., Xie D., Shi J., Huang W., Xu G., Peng M., Han J., Li R., Yang S., Wei Y. Semi-synthesis and anti-proliferative activity evaluation of novel analogues of Honokiol. Bioorg. Med. Chem. Lett. 2009, 19:4702-4705.
21. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
22. Russo G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol. 2007, 74:533-544.
23. Li W., Wang Q., Su Q., Ma D., An C., Ma L., Liang H. Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling. Mol. Cells 2014, 37:383-388.
24. Chen X.R., Lu R., Dan H.X., Liao G., Zhou M., Li X.Y., Ji N. Honokiol: A promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells. Int. J. Oral Sci. 2011, 3:34-42.
25. Kim D.W., Ko S.M., Jeon Y.J., Noh Y.W., Choi N.J., Cho S.D., Moon H.S., Cho Y.S., Shin J.C., Park S.M., Seo K.S., Choi J.Y., Chae J.I., Shim J.H. Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1. Int. J. Oncol. 2013, 43:1103-1110.
26. Battle T.E., Arbiser J., Frank D.A. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 2005, 106:690-697.
27. Kaushik G., Ramalingam S., Subramaniam D., Rangarajan P., Protti P., Rammamoorthy P., Anant S., Mammen J.M. Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. Am. J. Surg. 2012, 204:868-873.
28. Ponnurangam S., Mammen J.M., Ramalingam S., He Z., Zhang Y., Umar S., Subramaniam D., Anant S. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol. Cancer Ther. 2012, 11:963-972.
29. Hua H., Chen W., Shen L., Sheng Q., Teng L. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells. Acta Biochim. Biophys. Sin. (Shanghai) 2013, 45:773-779.
30. Liu H., Zang C., Emde A., Planas-Silva M.D., Rosche M., Kuhnl A., Schulz C.O., Elstner E., Possinger K., Eucker J. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur. J. Pharmacol. 2008, 591:43-51.
31. Singh T., Katiyar S.K. Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2. Int. J. Oncol. 2011, 38:769-776.
32. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21:99-102.
33. Luo H., Zhong Q., Chen L.J., Qi X.R., Fu A.F., Yang H.S., Yang F., Lin H.G., Wei Y.Q., Zhao X. Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer. J. Cancer Res. Clin. Oncol. 2008, 134:937-945.
34. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 1997, 3:1034-1036.
35. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science 1994, 266:1821-1828.
36. Park E.J., Min H.Y., Chung H.J., Hong J.Y., Kang Y.J., Hung T.M., Youn U.J., Kim Y.S., Bae K., Kang S.S., Lee S.K. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett. 2009, 277:133-140.
37. Ishikawa C., Arbiser J.L., Mori N. Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia. Biochim. Biophys. Acta 2012, 1820:879-887.
38. Hahm E.R., Singh S.V. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol. Cancer Ther. 2007, 6:2686-2695.
39. Chilampalli C., Guillermo R., Kaushik R.S., Young A., Chandrasekher G., Fahmy H., Dwivedi C. Honokiol, a chemopreventive agent against skin cancer, induces cell cycle arrest and apoptosis in human epidermoid A431 cells. Exp. Biol. Med. (Maywood) 2011, 236:1351-1359.
40. Yang G.L., Hou W.L., Fu A.F., Zhong Z.H., Yin X.H., Chen L.J. Effects of honokiol on proliferation and apoptosis of human cervical carcinoma cell line Hela in vitro. Sichuan Da Xue Xue Bao Yi Xue Ban 2008, 39:558-562.
41. Hahm E.R., Arlotti J.A., Marynowski S.W., Singh S.V. Honokiol, a constituent of oriental medicinal herb Magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin. Cancer Res. 2008, 14:1248-1257.
42. Wang T., Chen F., Chen Z., Wu Y.F., Xu X.L., Zheng S., Hu X. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J. Gastroenterol. 2004, 10:2205-2208.
43. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
44. Kim G.D., Bae S.Y., Park H.J., Bae K., Lee S.K. Honokiol inhibits vascular vessel formation of mouse embryonic stem cell-derived endothelial cells via the suppression of PECAM and MAPK/mTOR signaling pathway. Cell. Physiol. Biochem. 2012, 30:758-770.
45. Klein C.A. Cancer. The metastasis cascade. Science 2008, 321:1785-1787.
46. Nagalingam A., Arbiser J.L., Bonner M.Y., Saxena N.K., Sharma D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res. 2012, 14:R35.
47. Rajendran P., Li F., Shanmugam M.K., Vali S., Abbasi T., Kapoor S., Ahn K.S., Kumar A.P., Sethi G. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J. Cell. Physiol. 2012, 227:2184-2195.
48. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
49. Yu C., Zhang Q., Zhang H.Y., Zhang X., Huo X., Cheng E., Wang D.H., Arbiser J.L., Spechler S.J., Souza R.F. Targeting the intrinsic inflammatory pathway: Honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G561-G569.
50. Avtanski D.B., Nagalingam A., Bonner M.Y., Arbiser J.L., Saxena N.K., Sharma D. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol. Oncol. 2014, 8:565-580.
51. Dyson H.J., Komives E.A. Role of disorder in IkappaB-NFkappaB interaction. IUBMB Life 2012, 64:499-505.
52. Shen H.M., Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363.
53. Ahn K.S., Sethi G., Shishodia S., Sung B., Arbiser J.L., Aggarwal B.B. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol. Cancer Res. 2006, 4:621-633.
54. Karin M., Delhase M. The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin. Immunol. 2000, 12:85-98.
55. Lien W.H., Fuchs E. Wnt some lose some: Transcriptional governance of stem cells by Wnt/beta-catenin signaling. Genes Dev. 2014, 28:1517-1532.
56. Trompouki E., Bowman T.V., Lawton L.N., Fan Z.P., Wu D.C., DiBiase A., Martin C.S., Cech J.N., Sessa A.K., Leblanc J.L., Li P., Durand E.M., Mosimann C., Heffner G.C., Daley G.Q., Paulson R.F., Young R.A., Zon L.I. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell 2011, 147:577-589.
57. Morin P.J. Beta-catenin signaling and cancer. Bioessays 1999, 21:1021-1030.
58. Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V., Dale T.C., Pearl L.H. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 2003, 22:494-501.
59. Yao C.J., Lai G.M., Yeh C.T., Lai M.T., Shih P.H., Chao W.J., Whang-Peng J., Chuang S.E., Lai T.Y. Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/beta-catenin signaling and apoptosis induction. Evid. Based Complement. Alternat. Med. 2013, 2013:146136. 10.1155/2013/146136.
60. Jeong J.J., Lee J.H., Chang K.C., Kim H.J. Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules. Int. J. Oncol. 2012, 41:1358-1364.
61. Crane C., Panner A., Pieper R.O., Arbiser J., Parsa A.T. Honokiol-mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J. Immunother. 2009, 32:585-592.
62. Leeman-Neill R.J., Cai Q., Joyce S.C., Thomas S.M., Bhola N.E., Neill D.B., Arbiser J.L., Grandis J.R. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin. Cancer Res. 2010, 16:2571-2579.
63. Wang X., Beitler J.J., Wang H., Lee M.J., Huang W., Koenig L., Nannapaneni S., Amin A.R., Bonner M., Shin H.J., Chen Z.G., Arbiser J.L., Shin D.M. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS One 2014, 9:e86369.
64. Hall K., Ran S. Regulation of tumor angiogenesis by the local environment. Front. Biosci. (Landmark Ed.) 2010, 15(195-212):195-212.
65. Hua K.T., Lee W.J., Yang S.F., Chen C.K., Hsiao M., Ku C.C., Wei L.H., Kuo M.L., Chien M.H. Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. Biochim. Biophys. Acta 2014, 1843:387-397.
66. Wen J., Fu A.F., Chen L.J., Xie X.J., Yang G.L., Chen X.C., Wang Y.S., Li J., Chen P., Tang M.H., Shao X.M., Lu Y., Zhao X., Wei Y.Q. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int. J. Cancer 2009, 124:2709-2718.
67. Vavilala D.T., Ponnaluri V.K., Vadlapatla R.K., Pal D., Mitra A.K., Mukherji M. Honokiol inhibits HIF pathway and hypoxia-induced expression of histone lysine demethylases. Biochem. Biophys. Res. Commun. 2012, 422:369-374.
68. Lan K.L., Lan K.H., Sheu M.L., Chen M.Y., Shih Y.S., Hsu F.C., Wang H.M., Liu R.S., Yen S.H. Honokiol inhibits hypoxia-inducible factor-1 pathway. Int. J. Radiat. Biol. 2011, 87:579-590.
69. Ponnaluri V.K., Vavilala D.T., Prakash S., Mukherji M. Hypoxia mediated expression of stem cell markers in VHL-associated hemangioblastomas. Biochem. Biophys. Res. Commun. 2013, 438:71-77.
70. Dannenberg A.J., Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 2003, 4:431-436.
71. Liu S.H., Shen C.C., Yi Y.C., Tsai J.J., Wang C.C., Chueh J.T., Lin K.L., Lee T.C., Pan H.C., Sheu M.L. Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals. Br. J. Pharmacol. 2010, 160:1963-1972.
72. Tsai T.H., Chou C.J., Cheng F.C., Chen C.F. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 1994, 655:41-45.
73. Chen F., Wang T., Wu Y.F., Gu Y., Xu X.L., Zheng S., Hu X. Honokiol: A potent chemotherapy candidate for human colorectal carcinoma. World J. Gastroenterol. 2004, 10:3459-3463.
74. Su W.J., Huang X., Qin E., Jiang L., Ren P. Pharmacokinetics of honokiol in rat after oral administration of cortex of Magnolia officinalis and its compound preparation Houpu Sanwu decoction. Zhong Yao Cai 2008, 31:255-258.
75. Wu X., Chen X., Hu Z. High-performance liquid chromatographic method for simultaneous determination of honokiol and magnolol in rat plasma. Talanta 2003, 59:115-121.
76. Bohmdorfer M., Maier-Salamon A., Taferner B., Reznicek G., Thalhammer T., Hering S., Hufner A., Schuhly W., Jager W. In vitro metabolism and disposition of honokiol in rat and human livers. J. Pharm. Sci. 2011, 100:3506-3516.
77. Wang X.H., Cai L.L., Zhang X.Y., Deng L.Y., Zheng H., Deng C.Y., Wen J.L., Zhao X., Wei Y.Q., Chen L.J. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. Int. J. Pharm. 2011, 410:169-174.
78. Jiang Q.Q., Fan L.Y., Yang G.L., Guo W.H., Hou W.L., Chen L.J., Wei Y.Q. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer 2008, 8:242.